Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding Delayed Form 20-F Filings

November 26, 2026

BEIJING, Nov. 26, 2026 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter (the "Letter") from NYSE Regulation of the New York Stock Exchange (the "NYSE") dated November 23, 2026, notifying the Company that it is not in compliance with Section 802.01E of the NYSE Listed Company Manual because it has not yet filed restated financial statements for the fiscal years ended December 31, 2024 and 2025, including its amended Annual Reports on Form 20-F for those fiscal years (the "Delayed Filings"), within 60 days of its non-reliance disclosure. The Letter is a procedural notification under the NYSE's continued listing rules and relates to the timing of the Company's periodic reporting. It is only a notification and does not result in any immediate delisting or suspension of trading of the Company's American depositary shares. The Letter does not affect the Company's day-to-day business or operations. The Company currently expects to file the Delayed Filings by December 31, 2026.

As previously disclosed on September 22, 2026, following a letter from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission, the Company concluded that its previously issued audited consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2025, each as included in the Company's annual reports on Form 20-F for the respective fiscal years, should no longer be relied upon and will need to be restated to reflect the deconsolidation of Concord Healthcare Group Co., Ltd. effective in 2024. The restatement, which requires the Company and its independent auditors to complete the accounting and audit work relating to the deconsolidation, is currently in progress.

Under NYSE rules, the Company has six months from November 23, 2026 to file the Delayed Filings, and the NYSE may, in its discretion, grant an additional period of up to six months. If the Company does not regain compliance within the applicable cure period, or if intervening events occur before the cure period expires, the NYSE may commence suspension and delisting procedures. During this period, the Company will be included on the late filers list on the NYSE's website, and an "LF" indicator will be appended to the Company's listed securities on the NYSE's website and on the consolidated tape, until the Company is current with its SEC filing requirements.

The Company is working diligently, together with its independent auditors and advisors, to complete the restatement and to file the Delayed Filings as promptly as practicable.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement, including those relating to the Company's ability to complete the restatement and to timely file the Delayed Filings and to regain compliance with the NYSE's continued listing standards. The Company can give no assurance as to the timing or outcome of these efforts. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

View original content:https://www.prnewswire.com/news-releases/concord-medical-announces-receipt-of-nyse-non-compliance-letter-regarding-delayed-form-20-f-filings-302951152.html

SOURCE Concord Medical Services Holdings Limited

Concord Medical Services Holdings Limited, Investor Relations, +86 10 5903 6688, ir@ccm.cn